Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC increased its stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) by 74.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,317 shares of the biotechnology company’s stock after buying an additional 6,552 shares during the quarter. SG Americas Securities LLC’s holdings in Capricor Therapeutics were worth $211,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in CAPR. The Manufacturers Life Insurance Company acquired a new position in shares of Capricor Therapeutics during the third quarter valued at $161,000. Sassicaia Capital Advisers LLC bought a new stake in Capricor Therapeutics in the 3rd quarter valued at about $192,000. BNP Paribas Financial Markets boosted its stake in Capricor Therapeutics by 868.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock valued at $269,000 after purchasing an additional 15,872 shares during the period. Magnus Financial Group LLC bought a new position in Capricor Therapeutics in the 4th quarter worth about $276,000. Finally, Krilogy Financial LLC acquired a new stake in shares of Capricor Therapeutics in the fourth quarter valued at approximately $287,000. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Price Performance

Shares of NASDAQ:CAPR opened at $14.09 on Friday. The stock’s 50 day moving average price is $14.34 and its 200 day moving average price is $12.46. The stock has a market cap of $640.67 million, a price-to-earnings ratio of -13.29 and a beta of 4.08. Capricor Therapeutics Inc has a 12 month low of $3.52 and a 12 month high of $23.40.

Wall Street Analyst Weigh In

CAPR has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, January 2nd. Piper Sandler started coverage on Capricor Therapeutics in a research report on Monday, October 21st. They set an “overweight” rating and a $35.00 price target for the company. Finally, Cantor Fitzgerald increased their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.